Corteva (CTVA) announced that the company that will comprise its current advanced seed and genetics business will be branded Vylor. Corteva’s planned separation remains on track for Q4. With more than 4,000 germplasm patents and more than 2,000 biotechnology patents, Vylor’s innovation engine will be anchored in the industry’s germplasm and transformative biotechnology.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTVA:
- Corteva Shareholders Support Directors, Pay and Auditor at Meeting
- Corteva price target raised to $95 from $89 at RBC Capital
- Corteva price target raised to $89 from $86 at Oppenheimer
- Corteva price target raised to $90 from $85 at Wells Fargo
- Corteva Announces Leadership Changes Ahead of Seed Spin-Off